2017 American Society of Hematology Annual Meeting*

Download All
December 9-12, 2017; Atlanta, Georgia
John M. Burke, MD, and Christopher R. Flowers, MD, review and share their expert perspectives on key findings in lymphoma/CLL presented at the 2017 ASH annual meeting.
John M. Burke, MD
Christopher R. Flowers, MD, MS


In this pooled analysis, median PFS was nearly 4 years and duration of response was nearly 4.5 years for those patients with relapsed/refractory MCL who achieved a CR with single agent ibrutinib therapy.

Released: December 13, 2017

After a median follow-up of nearly 5 years, initial treatment with lenalidomide plus rituximab achieved a CR rate of 61%, with many patients in CR achieving MRD negativity.

Released: December 14, 2017

In patients with R/R MCL, acalabrutinib monotherapy was associated with an ORR of 81% and ongoing responses at 12 months in 72% of these patients.

Released: December 11, 2017

High patient baseline levels of tumor burden, LDH, and inflammatory biomarkers were associated with high levels of CAR T-cell expansion but increased rates of CRS and neurotoxicity.

Released: December 20, 2017

The addition of polatuzumab vedotin to BR significantly increased ORR and CR rates in transplantation-ineligible patients with relapsed/refractory DLBCL vs BR alone.

Released: December 15, 2017

A CR was achieved in 100% of patients with R/R HCL treated with the chemotherapy-free combination of vemurafenib plus rituximab.

Released: December 11, 2017

Ibrutinib plus venetoclax for 6 months achieved deep responses with 1 in 3 patients attaining minimal residual disease–negative bone marrow.

Released: December 19, 2017

In this interim analysis, venetoclax plus ibrutinib combination therapy achieved high response rates in patients with CLL, with many patients achieving MRD-negative bone marrow.

Released: December 12, 2017

In patients with FL treated with BR induction therapy, 4 years vs 2 years of rituximab maintenance appears to improve PFS.

Released: December 20, 2017

Tisagenlecleucel (CTL019) demonstrated an ORR of 53% with most CRs sustained at 6 months in patients with hard-to-treat relapsed/refractory DLBCL.

Released: December 15, 2017

The chemotherapy-free combination of brentuximab vedotin plus nivolumab achieved a CR of 62% as first salvage therapy in patients with relapsed/refractory classical Hodgkin lymphoma without adverse effects on subsequent transplantation.

Released: December 18, 2017

In patients with R/R cHL who continued nivolumab treatment following progression, 53% experienced reductions in tumor burden.

Released: December 14, 2017

Brentuximab vedotin plus AVD reduced the risk of progression, death, or need for further anticancer therapy by 23% vs standard ABVD in patients with previously untreated advanced classical Hodgkin lymphoma.

Released: December 14, 2017

In this expert analysis, John M. Burke, MD, and Christopher R. Flowers, MD, review and provide their perspective on key lymphomas and CLL studies presented at the Hematology 2017 annual meeting.

John M. Burke, MD Christopher R. Flowers, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 27, 2018 Expired: No longer available for credit

In a preplanned interim analysis of this phase III study, venetoclax plus rituximab significantly improved median PFS independent of del(17p) status vs bendamustine plus rituximab, with 60% of patients maintaining MRD negativity at 18 months.

Released: December 15, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Celgene Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics Inc.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings